Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cantonal Hospital of St. Gallen
Longitudinal ex vivo and in vitro study to determine the effect of natalizumab on frequency of distinct immune cells and on the frequency and suppressive function of natural CD4+CD25+ regulatory T cells (Tregs).
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
relapsing remitting MS
indication for natalizumab treatment
You may not be if
other disease modifying agents within 2 weeks
Clareo Health | Differential Immune Effects of Natalizumab
